FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023486602> ?p ?o ?g. }

• W2023486602 endingPage "1571" @default.
• W2023486602 startingPage "1570" @default.
• W2023486602 abstract "HomeStrokeVol. 36, No. 7Editorial Comment—Brain Natriuretic Peptide and Early Cardiac Dysfunction After Subarachnoid Hemorrhage Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBEditorial Comment—Brain Natriuretic Peptide and Early Cardiac Dysfunction After Subarachnoid Hemorrhage Martin Schillinger Martin SchillingerMartin Schillinger Department of Internal Medicine II, Division of Angiology, University of Vienna, Medical School, Vienna, Austria Search for more papers by this author Originally published9 Jun 2005https://doi.org/10.1161/01.STR.0000170716.51658.a7Stroke. 2005;36:1570–1571Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: June 9, 2005: Previous Version 1 Subarachnoid hemorrhage (SAH) can be a catastrophic event for the brain and patients’ neurocognitive function; however, SAH also exerts cardiac adverse effects causing rhythm disturbances or myocardial necrosis in up to 40% of the patients.1–3 Evidence suggests that an increased sympathetic nervous activity and excessive catecholamine release during and after the event may cause deterioration of cardiac function.4 In this context, Tung et al demonstrated previously that the degree of neurological injury correlates with the extent of cardiac damage.5 Cardiac dysfunction after SAH adversely affects patients’ overall prognosis3 and, more specifically, the clinical sequelae of heart failure, namely low-output and hypotension, negatively influence neurological outcome after hemorrhagic brain injury. Early identification and monitoring of cardiac dysfunction thus is becoming increasingly recognized as a critical issue in patients with SAH.6A variety of laboratory parameters may yield prognostic information on cardiac function in SAH patients. Among the panel of promising biomarkers, mainly parameters indicative for myocardial necrosis like cardiac troponins or creatine kinase MB fraction have been studied,7 and, particularly, troponin I seems to be useful in predicting ischemia-related myocardial dysfunction.7 During the past decade, natriuretic peptides emerged as novel and potentially powerful cardiovascular risk predictors and unequivocally have been shown to predict outcome of patients with heart failure and coronary artery and valvular heart disease.8–11 Brain natriuretic peptide (BNP) is synthesized as a pro-hormone in ventricular cardiocytes in response to cardiac wall stress and pressure overload, and is cleaved into the active BNP and inactive N-terminal pro-brain natriuretic peptide (NT-proBNP). Levels of BNP correlate with left ventricular dilatation and dysfunction12 and were initially recognized mainly as markers of chronic heart failure.13 More recently, BNP was established also as a sensitive prognostic parameter in patients with myocardial ischemia.8,9 It has been shown that even transient myocardial ischemia results in an immediate increase of BNP, with the magnitude of the increase proportional to the severity of ischemia.14 It is well-recognized, that BNP is elevated after SAH, but the source of its release and its prognostic impact remained to be determined.In this issue of Stroke, Tung et al15 report the association between serum BNP levels measured in 57 patients after SAH and occurrence of cardiac dysfunction by echocardiography and cardiac troponin I elevation. BNP was significantly associated with all measures of cardiac dysfunction: higher BNP values were observed in patients with regional wall motion abnormalities, reduced left ventricular function, diastolic dysfunction, pulmonary edema, and cardiac troponin I elevation. Furthermore, BNP levels were associated with in-hospital mortality. The authors concluded that cardiac injury occurring early after SAH is associated with BNP elevation, supporting the hypothesis that the increase of BNP levels frequently observed after SAH is caused by BNP release from the heart. Importantly, elevated BNP was also identified as a prognostic marker with respect to early mortality in these patients.Discussing the implications of this report several interesting issues arise. The data from Tung et al15 seem to support the notion that the heart is the source of BNP release after SAH rather than being derived from the brain. However, BNP elevation after SAH seems to directly reflect the extent of cardiac deterioration in these patients, which may be useful for routine clinical applications. BNP is a global indicator of cardiac dysfunction,13 sensitive both for systolic and diastolic cardiac deterioration.12,16 After SAH, electrocardiogram has its limitations in detecting myocardial necrosis as changes in waveforms are largely neurally mediated and myocardial lesions tend to be small and patchy.1 Currently, echocardiography therefore is considered the golden standard to detect cardiac dysfunction after SAH, but daily investigations and close monitoring of SAH patients by echocardiography does not seem feasible on a routine basis, and many SAH patients will undergo echocardiography only in cases of clinical evidence for heart failure. Routine measurements of BNP thus may provide a tool to monitor cardiac function and enable early identification of patients with incipient heart failure after SAH. Importantly, patients with higher BNP levels had an increased risk for in-hospital mortality, but the question whether therapeutic interventions may improve the prognosis of patients with BNP elevation after SAH remains unresolved and needs further evaluation. In the context of coronary artery disease, controversial data exist. A substudy of FRISC II indicated a survival benefit from early revascularization of patients with elevated levels of NT-proBNP,17 TACTICS-TIMI-18,18 in contrast, suggested that revascularization did not benefit patients with elevated BNP levels.Some limitations of the study by Tung et al15 seem worth further consideration. First, although “prospective,” the analytic character of this study remains cross-sectional. Blood samples for BNP measurements were obtained on average 5 days after onset of SAH symptoms and BNP was correlated with abnormal cardiac results “on any of the 3 study days.” Without knowing the baseline levels of BNP before the event (which rarely can be obtained) or at least very early BNP measurements, it is virtually impossible to differentiate between BNP elevation caused by preexistent chronic cardiac pathologies and BNP increase in parallel with acute cardiac dysfunction caused by SAH. Second, only a subset of 57 of 174 patients was available to study BNP levels and clinical follow-up was limited to hospital discharge. Confirmation of these data in larger patient series and prolonged neurological and cardiovascular follow-up seems important before considering BNP measurements after SAH in clinical routine.In conclusion, the findings by Tung et al suggest that patients with cardiac injury and dysfunction early after SAH can be identified by measurement of BNP levels and that elevation of BNP may be of immediate prognostic importance.References1001 Homma S, Grahame-Clarke C. Myocardial damage in patients with subarachnoid hemorrhage. Stroke. 2004; 35: 552.LinkGoogle Scholar1001 Mayer SA, Lin J, Homma S, Solomon RA, Lennihan L, Sherman D, Fink ME, Beckford A, Klebanoff LM. Myocardial injury and left ventricular performance after subarachnoid hemorrhage. Stroke. 1999; 30: 780–786.CrossrefMedlineGoogle Scholar1001 Crago EA, Kerr ME, Kong Y, Baldisseri M, Horowitz M, Yonas H, Kassam A. The impact of cardiac complications on outcome in the SAH population. Acta Neurol Scand. 2004; 110: 248–253.CrossrefMedlineGoogle Scholar1001 Masuda T, Sato K, Yamamoto S, Matsuyama N, Shimohama T, Matsunaga A, Obuchi S, Shiba Y, Shimizu S, Izumi T. Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model. Stroke. 2002; 33: 1671–1676.LinkGoogle Scholar1001 Tung P, Kopelnik A, Banki N, Ong K, Ko N, Lawton MT, Gress D, Drew B, Foster E, Parmley W, Zaroff J. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. Stroke. 2004; 35: 548–551.LinkGoogle Scholar1001 Macmillan CS, Grant IS, Andrews PJ. Pulmonary and cardiac sequelae of subarachnoid hemorrhage: time for active management? Intesive Care Med. 2002; 28: 1012–1023.CrossrefMedlineGoogle Scholar1001 Parekh N, Venkatesh B, Cross D, Leditschke A, Atherton J, Miles W, Winning A, Clague A, Rickard C. Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage. J Am Coll Cardiol. 2000; 36: 1328–1335.CrossrefMedlineGoogle Scholar1001 de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345: 1014–1021.CrossrefMedlineGoogle Scholar1001 Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004; 350: 655–663.CrossrefMedlineGoogle Scholar1001 Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002; 105: 2392–2397.LinkGoogle Scholar1001 Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, Binder T, Pacher R, Maurer G, Baumgartner H. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation. 2004; 109: 2302–2308.LinkGoogle Scholar1001 Groenning BA, Nilsson JC, Sondergaard L, Pedersen F, Trawinski J, Baumann M, Larsson HB, Hildebrandt PR. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J. 2002; 143: 923–929.CrossrefMedlineGoogle Scholar1001 Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med. 2004; 164: 1978–1984.CrossrefMedlineGoogle Scholar1001 Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, Hall C, McCabe CH, Braunwald E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004; 44: 1988–1995.CrossrefMedlineGoogle Scholar1001 Tung PP, Olmsted E, Kopelnik A, Banki, NM, Drew BJ, Ko N, Lawton MT, Smith W, Foster E, Young WL, Zaroff JG. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage. Stroke. 2005; 36: 1567–1571.LinkGoogle Scholar1001 Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Gardetto N, Wanner E, Maisel AS. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002; 105: 595–601.CrossrefMedlineGoogle Scholar1001 Jernberg T, Lindhal B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, Stridsberg M, Venge P, Wallentin L. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of invasive strategy in unstable coronary syndrome. J Am Coll Cardiol. 2003; 42: 1909–1916.CrossrefMedlineGoogle Scholar1001 Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI-18. J Am Coll Cardiol. 2003; 41: 1264–1272.CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Ripoll J, Blackshear J and Díaz-Gómez J (2018) Acute Cardiac Complications in Critical Brain Disease, Neurosurgery Clinics of North America, 10.1016/j.nec.2017.11.007, 29:2, (281-297), Online publication date: 1-Apr-2018. Ripoll J, Blackshear J and Díaz-Gómez J (2017) Acute Cardiac Complications in Critical Brain Disease, Neurologic Clinics, 10.1016/j.ncl.2017.06.011, 35:4, (761-783), Online publication date: 1-Nov-2017. McAteer A, Hravnak M, Chang Y, Crago E, Gallek M and Yousef K (2017) The Relationships Between BNP and Neurocardiac Injury Severity, Noninvasive Cardiac Output, and Outcomes After Aneurysmal Subarachnoid Hemorrhage, Biological Research For Nursing, 10.1177/1099800417711584, 19:5, (531-537), Online publication date: 1-Oct-2017. Apostolakis E, Parissis H and Dougenis D (2010) Brain Death and Donor Heart Dysfunction: Implications in Cardiac Transplantation, Journal of Cardiac Surgery, 10.1111/j.1540-8191.2008.00790.x, 25:1, (98-106), Online publication date: 1-Jan-2010. July 2005Vol 36, Issue 7 Advertisement Article InformationMetrics https://doi.org/10.1161/01.STR.0000170716.51658.a7PMID: 15947256 Originally publishedJune 9, 2005 PDF download Advertisement" @default.
• W2023486602 created "2016-06-24" @default.
• W2023486602 creator A5044482489 @default.
• W2023486602 date "2005-07-01" @default.
• W2023486602 modified "2023-09-27" @default.
• W2023486602 title "Editorial Comment—Brain Natriuretic Peptide and Early Cardiac Dysfunction After Subarachnoid Hemorrhage" @default.
• W2023486602 cites W1986122868 @default.
• W2023486602 cites W2002915455 @default.
• W2023486602 cites W2003709982 @default.
• W2023486602 cites W2006287148 @default.
• W2023486602 cites W2019138833 @default.
• W2023486602 cites W2022349760 @default.
• W2023486602 cites W2025576182 @default.
• W2023486602 cites W2061724830 @default.
• W2023486602 cites W2080366036 @default.
• W2023486602 cites W2096667661 @default.
• W2023486602 cites W2106709122 @default.
• W2023486602 cites W2136765979 @default.
• W2023486602 cites W2149794785 @default.
• W2023486602 cites W2150359689 @default.
• W2023486602 cites W2155970093 @default.
• W2023486602 cites W4249406366 @default.
• W2023486602 doi "https://doi.org/10.1161/01.str.0000170716.51658.a7" @default.
• W2023486602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15947256" @default.
• W2023486602 hasPublicationYear "2005" @default.
• W2023486602 type Work @default.
• W2023486602 sameAs 2023486602 @default.
• W2023486602 citedByCount "5" @default.
• W2023486602 countsByYear W20234866022017 @default.
• W2023486602 countsByYear W20234866022018 @default.
• W2023486602 crossrefType "journal-article" @default.
• W2023486602 hasAuthorship W2023486602A5044482489 @default.
• W2023486602 hasBestOaLocation W20234866021 @default.
• W2023486602 hasConcept C126322002 @default.
• W2023486602 hasConcept C164705383 @default.
• W2023486602 hasConcept C2775846464 @default.
• W2023486602 hasConcept C2775915353 @default.
• W2023486602 hasConcept C2777736543 @default.
• W2023486602 hasConcept C2778198053 @default.
• W2023486602 hasConcept C2993469949 @default.
• W2023486602 hasConcept C71924100 @default.
• W2023486602 hasConceptScore W2023486602C126322002 @default.
• W2023486602 hasConceptScore W2023486602C164705383 @default.
• W2023486602 hasConceptScore W2023486602C2775846464 @default.
• W2023486602 hasConceptScore W2023486602C2775915353 @default.
• W2023486602 hasConceptScore W2023486602C2777736543 @default.
• W2023486602 hasConceptScore W2023486602C2778198053 @default.
• W2023486602 hasConceptScore W2023486602C2993469949 @default.
• W2023486602 hasConceptScore W2023486602C71924100 @default.
• W2023486602 hasIssue "7" @default.
• W2023486602 hasLocation W20234866021 @default.
• W2023486602 hasLocation W20234866022 @default.
• W2023486602 hasOpenAccess W2023486602 @default.
• W2023486602 hasPrimaryLocation W20234866021 @default.
• W2023486602 hasRelatedWork W11304534 @default.
• W2023486602 hasRelatedWork W2008851126 @default.
• W2023486602 hasRelatedWork W2049397185 @default.
• W2023486602 hasRelatedWork W2074833529 @default.
• W2023486602 hasRelatedWork W2125804349 @default.
• W2023486602 hasRelatedWork W2161501502 @default.
• W2023486602 hasRelatedWork W2328354663 @default.
• W2023486602 hasRelatedWork W2355498105 @default.
• W2023486602 hasRelatedWork W2390185673 @default.
• W2023486602 hasRelatedWork W2886547040 @default.
• W2023486602 hasVolume "36" @default.
• W2023486602 isParatext "false" @default.
• W2023486602 isRetracted "false" @default.
• W2023486602 magId "2023486602" @default.
• W2023486602 workType "editorial" @default.